Preferred Label : Telisotuzumab Vedotin;
NCIt synonyms : ABT-700-VCMMAE;
NCIt definition : An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody
against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine
kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic
agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE;
vedotin), with potential antineoplastic activity. Upon intravenous administration,
the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met
expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the
cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits
tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis.
This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed
or mutated in many tumor cell types, plays key roles in tumor cell proliferation,
survival, invasion, metastasis and tumor angiogenesis.;
UNII : 976X9VXC3Z;
CAS number : 1714088-51-3;
Molecule name : ABT-399; ABBV-399; ABBV 399; ABT 399;
NCI Metathesaurus CUI : CL474084;
Origin ID : C118571;
UMLS CUI : C4743550;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
